Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia
Introduction Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative sy...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-03-01
|
| Series: | European Psychiatry |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823022617/type/journal_article |
| _version_ | 1797616052329250816 |
|---|---|
| author | Z. Mielczarek B. Trędzbor K. Krysta |
| author_facet | Z. Mielczarek B. Trędzbor K. Krysta |
| author_sort | Z. Mielczarek |
| collection | DOAJ |
| description |
Introduction
Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative symptoms and cognitive functions. It is a medicine with a multi-receptor mechanism of action: it mainly blocks dopaminergic D2 and serotonergic 5-HT2A receptors. According to the Summary of Product Characteristics, adverse reactions such as leucopenia, neutropenia and anaemia were too rare to estimate their frequency.
Objectives
This study describes case of neutrocytopenia and leukocytopenia that are likely to be related to lurasidone and have resolved after discontinuation of this medicinal product. The aim of the article is to highlight the risk of using second-generation antipsychotics in patients and the occurence of blood cells disorders in particular neutrocytopenia.
Methods
An analysis of the medical history records were done to describe the case report.
Results
39-years-old patient treated psychiatrically for 18 years, initially for mood disorders, irritability, behavioural disorders. In 2014 she was diagnosed with paranoid schizophrenia, herlast psychiatric hospitalization took place in 2021. The patient had a history of neutrocytopenia and leukocytopenia. In December 2020, the patient was admitted to the psychiatric ward on account of active aggression against her mother. She was discharged in January 2021 with the recommendation to take paliperidone intramusculary. Due to incomplete remission of psychotic symptoms, the patient received 37 mg of lurasidone since August 2021. The blood count, which was ordered upon admission to the Department of Psychiatric Rehabilitation, showed moderate neutrocytopenia. After discontinuation of lurasidone and the recommended supplementation, the results gradually improved and finally reached the normal range.
Blood cells type
23.09.2021 r.
04.10.2021 r.
14.10.2021 r.
28.10.2021 r.
10.11.2021 r.
24.11.2021 r.
08.12.2021 r.
Leukocytes
2,45 x 10^3/μl
2,73 x 10^3/μl
2,39 x 10^3/μl
2,66 x 10^3/μl
2,79 x 10^3/μl
4,09 x 10^3/μl
4,03 x 10^3/μl
Erythrocytes
4,26 x 10^3/μl
4,31 x 10^3/μl
4,48 x 10^3/μl
4,06 x 10^3/μl
4,08 x 10^3/μl
4,39 x 10^3/μl
4,22 x 10^3/μlb
Neutrocytes
1,04 x 10^3/μl
1,60 x 10^3/μl
1,24 x 10^3/μl
1,53 x 10^3/μl
1,78 x 10^3/μl
2,72 x 10^3/μl
2,62 x 10^3/μl
Lymphocytes
1,05 x 10^3/μl
0,70 x 10^3/μl
0,72 x 10^3/μl
0,73 x 10^3/μl
0,64 x 10^3/μl
0,83 x 10^3/μl
0,92 x 10^3/μl
Conclusions
This case report shows the need for regular monitoring of blood cells parameters in patients treated with second generation antipsychotics, as there is a risk of neutrocytopenia or even agranulocitosis. If there is an obvious correlation, the dose should be reduced or switched to another medicinal product if possible and blood counts should monitored further.
Disclosure of Interest
None Declared |
| first_indexed | 2024-03-11T07:35:42Z |
| format | Article |
| id | doaj.art-34fdb66379c540e383b14391f88588b3 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:35:42Z |
| publishDate | 2023-03-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-34fdb66379c540e383b14391f88588b32023-11-17T05:09:55ZengCambridge University PressEuropean Psychiatry0924-93381778-35852023-03-0166S1065S106510.1192/j.eurpsy.2023.2261Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophreniaZ. Mielczarek0B. Trędzbor1K. Krysta2Students’ Scientific Association, Department of Rehabilitation PsychiatryDepartment of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, PolandDepartment of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland Introduction Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative symptoms and cognitive functions. It is a medicine with a multi-receptor mechanism of action: it mainly blocks dopaminergic D2 and serotonergic 5-HT2A receptors. According to the Summary of Product Characteristics, adverse reactions such as leucopenia, neutropenia and anaemia were too rare to estimate their frequency. Objectives This study describes case of neutrocytopenia and leukocytopenia that are likely to be related to lurasidone and have resolved after discontinuation of this medicinal product. The aim of the article is to highlight the risk of using second-generation antipsychotics in patients and the occurence of blood cells disorders in particular neutrocytopenia. Methods An analysis of the medical history records were done to describe the case report. Results 39-years-old patient treated psychiatrically for 18 years, initially for mood disorders, irritability, behavioural disorders. In 2014 she was diagnosed with paranoid schizophrenia, herlast psychiatric hospitalization took place in 2021. The patient had a history of neutrocytopenia and leukocytopenia. In December 2020, the patient was admitted to the psychiatric ward on account of active aggression against her mother. She was discharged in January 2021 with the recommendation to take paliperidone intramusculary. Due to incomplete remission of psychotic symptoms, the patient received 37 mg of lurasidone since August 2021. The blood count, which was ordered upon admission to the Department of Psychiatric Rehabilitation, showed moderate neutrocytopenia. After discontinuation of lurasidone and the recommended supplementation, the results gradually improved and finally reached the normal range. Blood cells type 23.09.2021 r. 04.10.2021 r. 14.10.2021 r. 28.10.2021 r. 10.11.2021 r. 24.11.2021 r. 08.12.2021 r. Leukocytes 2,45 x 10^3/μl 2,73 x 10^3/μl 2,39 x 10^3/μl 2,66 x 10^3/μl 2,79 x 10^3/μl 4,09 x 10^3/μl 4,03 x 10^3/μl Erythrocytes 4,26 x 10^3/μl 4,31 x 10^3/μl 4,48 x 10^3/μl 4,06 x 10^3/μl 4,08 x 10^3/μl 4,39 x 10^3/μl 4,22 x 10^3/μlb Neutrocytes 1,04 x 10^3/μl 1,60 x 10^3/μl 1,24 x 10^3/μl 1,53 x 10^3/μl 1,78 x 10^3/μl 2,72 x 10^3/μl 2,62 x 10^3/μl Lymphocytes 1,05 x 10^3/μl 0,70 x 10^3/μl 0,72 x 10^3/μl 0,73 x 10^3/μl 0,64 x 10^3/μl 0,83 x 10^3/μl 0,92 x 10^3/μl Conclusions This case report shows the need for regular monitoring of blood cells parameters in patients treated with second generation antipsychotics, as there is a risk of neutrocytopenia or even agranulocitosis. If there is an obvious correlation, the dose should be reduced or switched to another medicinal product if possible and blood counts should monitored further. Disclosure of Interest None Declaredhttps://www.cambridge.org/core/product/identifier/S0924933823022617/type/journal_article |
| spellingShingle | Z. Mielczarek B. Trędzbor K. Krysta Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia European Psychiatry |
| title | Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| title_full | Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| title_fullStr | Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| title_full_unstemmed | Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| title_short | Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| title_sort | neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia |
| url | https://www.cambridge.org/core/product/identifier/S0924933823022617/type/journal_article |
| work_keys_str_mv | AT zmielczarek neutrocytopeniaassociatedwithalurasidontherapyinapatientwithparanoidschizophrenia AT btredzbor neutrocytopeniaassociatedwithalurasidontherapyinapatientwithparanoidschizophrenia AT kkrysta neutrocytopeniaassociatedwithalurasidontherapyinapatientwithparanoidschizophrenia |